Pappas Capital Announces the Passing of…

CAMBRIDGE, Mass. – January 23, 2012 – Selventa™, a biomarker discovery company that enables personalized healthcare through stratification of patients based on disease-driving mechanisms, today announced that the U. S. Patent & Trademark Office has issued the Company U.S. Patent No 8,802,109, titled "Computer-aided Discovery of Biomarker Profiles in Complex Biological Systems." This patent, which was issued on December 20, 2011, relates to methods and techniques that facilitate discovery of biomarkers and thus aid in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.

In particular, the patent describes a method of biomarker discovery using a model representative of one or more causative biophysical or biochemical relationships underlying a biological state in a biological system of interest.  A candidate set of biological data is then compared against the model to discern a candidate biomarker for the biological state.  A sample received from a patient can then be assayed for the presence of the candidate biomarkers to discern a biological state of the patient.

"Using the technique, biomarkers may be developed to predict efficacy or toxic effects of a drug. This may permit a researcher or physician to know, in advance, whether the presenting patient will benefit from or be harmed by administration of the drug," said David de Graaf, Ph.D., President and CEO of Selventa. "In addition, the patented technique facilitates the development of biomarkers as diagnostics for a disease, as a means of making treatment decisions or as a means of stratifying patients in a clinical trial. This will likely improve the success of clinical trials by screening for subjects that are more likely to benefit from the drug and avoiding those who are unlikely to respond."

About Selventa
Founded in 2002 and privately-held, Selventa collaborates with partners to match the optimal treatments for the right patients. The company analyzes molecular patient data to identify key disease-driving mechanisms and accelerates the development process to clarify therapeutic and diagnostic decisions through identification and development of biomarkers for patient stratification. Selventa engages in strategic relationships with leading pharmaceutical and life science companies including clinical research organizations, diagnostic companies and reference laboratories to enable personalized healthcare primarily in autoimmune diseases and oncology.  For more information, visit www.selventa.com.

CAMBRIDGE, Mass.—Selventa, a personalized healthcare company focused on stratification of patients and development of predictive biomarker panels based on disease-driving mechanisms, recently formed a strategic scientific alliance with Linguamatics, a software solutions company that provides knowledge extraction through its I2E natural language processing (NLP) text-mining platform.   

The idea is to combine the analytical capabilities of both companies to efficiently extract complex life science knowledge in a computable, structured, biological expression language format that can be used to interpret large-scale experimental data in the context of published literature.

That format is BEL, a structured language designed to represent scientific findings in a computable form with supporting contextual information, such as tissue, disease, species and publication. BEL is use-neutral, notes Dr. David Milward, chief technology officer at Linguamatics, and it articulates an idea in a manner that is “unambiguous, terse and conveys the facts and associated contexts without loss or ambiguity.” BEL, along with the BEL Framework, is available through a portal to the scientific community to promote the collection, sharing and interchange of structured scientific knowledge. Selventa's discovery platform operates on top of a scientific knowledge base made up of a set of BEL statements.

“The Selventa and Linguamatics collaboration shows how precise, detailed information can be automatically extracted from the literature and provided in a format suitable for further analysis and reasoning,” says Milward. “This will allow reuse of knowledge from the literature, at greater scale and speed.”   Much of the business and the future of Selventa are tied into biomarker discovery and personalized healthcare, David de Graaf, CEO of Selventa, tells ddn.

“The way we get there is having qualified knowledge available to us and to other users and comparing it to patient data sets. It’s a matter of pulling together prior knowledge in a usable manner with the analytics on top,” he says.

He notes that well-structured knowledge is already being customized within the scientific realm by organizations that are able to generate knowledge bases in specific areas, but in many cases they are using resources in China and India, “and we can’t directly compete with that,” he adds. “But well-quantified and organized knowledge is something our clients need and that drew us to Linguamatics so that this general knowledge out there could be put in a more terse and usable form.”

By using NLP-based capabilities to efficiently identify and extract relationships hidden in unstructured text and generate structured data for comprehensive biological investigation and analysis, the I2E platform is said to offer dramatically increased speed, scale and reproducibility, and the possibility to efficiently go back into a textual data source to pull out additional information that has become relevant.

“This partnership is a great strategic fit to facilitate the representation of complex biological knowledge that can be recycled and maximized through our analytical platform,” said de Graaf in the news release about the deal. “Collaborating with Linguamatics will enable rapid yet comprehensive investigation of new areas of biology by extracting computable knowledge from unstructured text. This will lead to innovation on many fronts, such as next-generation sequencing, where well-structured information for reasoning has been limited.”

One of primary goals for Selventa in this partnership is to be able to stratify patients using biomarkers.   “We’re doing a lot of this kind of work through the BEL initiative with Pfizer and along with Linguamatics as well, de Graaf says. He tells ddn that his company has also talked to other people in the knowledge space, whether publishers or other makers of knowledge bases, to get the best data possible.

“When customers acquire their data sets they often acquire broad assets that are shallow. They cover a lot of territory, like everything about clinical trials or a particular kind of chemistry, but what they don’t do is get what they often really need, which might be everything relevant in a particular area, like multiple sclerosis or breast cancer,” de Graaf says. “So you want to go relatively narrow but much deeper by integrating resources, and this is where Linguamatics helps us meet customers’ needs. We have a set of analytic tools that analyze prior experimental data and compare to your current set of experiments, and Linguamatics provides us with a platform for generating well-quantified knowledge from that.”

Having worked at companies like AstraZeneca and Boehringer Ingelheim, de Graaf had previously been involved in the evaluation and acquisition of NLP tools, and says that he came into Selventa already knowing folks at Linguamatics, “and far as I’m concerned, they are a premier provider of NLP solutions,” he says. “Unlike with other NLP platforms, where they are not expandable, Linguamatics meets our needs because its flexible—we knew our platform would require lots of tweaking, and knocking on their door to get technology that could handle that was just logical.”

Looking toward the future, de Graaf says he plans to work with the “best of the best” to implement not only a set of tools to feed into BEL but also to discover and analyze biomarkers, better stratify patients and more.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Selventa™ today announced a continuation and expansion of its strategic partnership with the world’s largest pharmaceutical company, Pfizer Inc., in the areas of biological knowledge dissemination and drug safety. The scope of the new collaboration, co-funded by Pfizer, includes creating a publicly available version of Selventa’s Biological Expression Language (BEL) and associated BEL Framework that will enable organizations to capture, store, combine and use scientific knowledge across a wide range of scientific applications to help inform and streamline decision-making regarding drug targets. The collaboration includes establishing a community of BEL stakeholders and users, and the development of a BEL community portal to disseminate the technology to the scientific community at large.

“The structure of this joint effort enables Selventa to expand its existing technology to develop a knowledge-sharing portal that has the potential to benefit not only Pfizer scientists but also the entire scientific community,” said David de Graaf, President and CEO of Selventa. “We are extremely excited to take our collaboration to the next level and look forward with great anticipation at the prospect of opening our technology platform and working even more closely with cross-functional R&D teams at Pfizer.”

Until recently, Selventa had only used the Genstruct® Technology Platform (GTP) as an internal platform for collaborative research projects with Pfizer and other pharmaceutical partners. Through recent rebranding efforts and collaborations such as this, Selventa is currently transitioning its technology platform and business model to a more open, standards-based approach, thereby enabling broad adoption and use of Selventa tools, infrastructure and knowledge among its customers, their business partners, and the wider scientific community.

“Pfizer is pleased to be part of this collaboration,” said Denise Robinson-Gravatt, Head of Pfizer’s Drug Safety Technology. “The success of our industry to a large extent is determined by new drug innovation, so the more we can make broadly available to the scientific community open-source solutions involving non-proprietary research and technology tools, the more we’re facilitating innovation to occur, which ultimately is a win-win for all stakeholders involved – the scientific community, the pharmaceutical industry and patients.”

About Selventa

Founded in 2002 and privately-held, Selventa helps clients find optimal treatments for the right patients by offering scientific consulting services, software and strategic partnerships. The company analyzes molecular patient data, accelerates the development process and clarifies therapeutics and diagnostics decisions. Selventa engages in short-, mid- and long-term relationships with top-tier pharmaceutical and life science companies to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases, inflammation and drug safety.

SelventaTM, which evolved from Genstruct®, Inc. today announced that it has changed its name and launched a re-branded website as part of an initiative to provide innovative solutions for its client partners. The company’s core strengths embrace a customer-focused approach that leverages existing patient data and innovative analytics to help pharmaceutical and biotechnology partners accelerate development and clarify decisions on therapeutics and diagnostics.